Filing Analysis
⚠️ Delisting Notice
Filed May 29, 2026
🔴 CRITICAL
Actinium Pharmaceuticals received a notice from NYSE American on May 27, 2026, stating it is not in compliance with continued listing standards due to insufficient stockholders' equity. The company must submit a compliance plan by June 26, 2026, to avoid delisting proceedings.
🚩 Red Flags
- Stockholders' equity ($2.3M) is significantly below the $4.0M requirement.
- Chronic losses over the last five consecutive fiscal years.
- Multiple 8-K items (3.01, 7.01, 9.01) in a single filing.
- Risk of delisting if the plan is rejected or not implemented successfully.
📋 Key Facts
- Company failed to maintain the minimum stockholders' equity requirement of $4.0 million.
- As of March 31, 2026, reported stockholders' equity was approximately $2.3 million.
- The company has reported net losses in its last five fiscal years ended December 31, 2025.
- Deadline to submit a compliance plan to NYSE American is June 26, 2026.
- If a plan is accepted, the deadline to regain compliance is November 27, 2027.
- Common stock will now trade with a '.BC' indicator to denote non-compliance.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.